MX2013005522A - Enantiomero activo de dodecil-2-(n,n-dimetilamino)-propionato. - Google Patents

Enantiomero activo de dodecil-2-(n,n-dimetilamino)-propionato.

Info

Publication number
MX2013005522A
MX2013005522A MX2013005522A MX2013005522A MX2013005522A MX 2013005522 A MX2013005522 A MX 2013005522A MX 2013005522 A MX2013005522 A MX 2013005522A MX 2013005522 A MX2013005522 A MX 2013005522A MX 2013005522 A MX2013005522 A MX 2013005522A
Authority
MX
Mexico
Prior art keywords
dimethylamino
propionate
dodecyl
ddaip
active enantiomer
Prior art date
Application number
MX2013005522A
Other languages
English (en)
Inventor
Richard Martin
Bassam B Damaj
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of MX2013005522A publication Critical patent/MX2013005522A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El 2R-dodecil 2-(N,N-dimetilamino)propionato (R-DDAIP) proporciona una actividad mejorada inesperada en la facilitación del transporte de un compuesto farmacéuticamente activo a través de membranas y tejidos biológicos, en comparación con el S-DDAIP de la misma pureza enantiomérica, o el DDAIP racémico. También se proporciona el S-DDAIP purificado.
MX2013005522A 2010-12-02 2011-11-30 Enantiomero activo de dodecil-2-(n,n-dimetilamino)-propionato. MX2013005522A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41899610P 2010-12-02 2010-12-02
PCT/US2011/062579 WO2012075107A2 (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Publications (1)

Publication Number Publication Date
MX2013005522A true MX2013005522A (es) 2013-07-17

Family

ID=46172526

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005522A MX2013005522A (es) 2010-12-02 2011-11-30 Enantiomero activo de dodecil-2-(n,n-dimetilamino)-propionato.

Country Status (19)

Country Link
US (1) US20130267562A1 (es)
EP (1) EP2646015B1 (es)
JP (1) JP6109075B2 (es)
KR (1) KR102004552B1 (es)
CN (1) CN103930105B (es)
AU (2) AU2011336692B2 (es)
BR (1) BR112013012799A8 (es)
CA (1) CA2817417C (es)
CL (1) CL2013001391A1 (es)
CR (1) CR20130324A (es)
ES (1) ES2801999T3 (es)
IL (1) IL226173A (es)
MX (1) MX2013005522A (es)
NZ (1) NZ609826A (es)
PL (1) PL2646015T3 (es)
RU (1) RU2679308C2 (es)
SG (2) SG190199A1 (es)
WO (1) WO2012075107A2 (es)
ZA (1) ZA201304840B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028780A2 (en) * 2012-08-15 2014-02-20 Nexmed Holdings, Inc. Antifungal compounds and methods of use
US8900625B2 (en) 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
KR20050045946A (ko) * 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
JP4540667B2 (ja) * 2003-03-21 2010-09-08 ネクスメツド・ホールデイングス・インコーポレイテツド 抗真菌性ネイルコート
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
JP5619337B2 (ja) * 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
US20050113274A1 (en) * 2003-11-22 2005-05-26 Nadir Buyuktimkin Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
KR20130079382A (ko) * 2010-05-04 2013-07-10 넥스메드 홀딩스 인코포레이티드 소분자 치료제의 조성물
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Also Published As

Publication number Publication date
US20130267562A1 (en) 2013-10-10
RU2679308C2 (ru) 2019-02-07
JP6109075B2 (ja) 2017-04-05
IL226173A0 (en) 2013-07-31
SG190199A1 (en) 2013-06-28
CN103930105B (zh) 2019-11-01
KR102004552B1 (ko) 2019-10-01
ES2801999T3 (es) 2021-01-15
IL226173A (en) 2016-10-31
KR20140023875A (ko) 2014-02-27
CR20130324A (es) 2013-08-13
AU2017200314A1 (en) 2017-02-02
SG10201803321TA (en) 2018-06-28
EP2646015A2 (en) 2013-10-09
CL2013001391A1 (es) 2013-11-08
NZ609826A (en) 2016-03-31
WO2012075107A3 (en) 2014-03-06
BR112013012799A2 (pt) 2016-09-13
CA2817417A1 (en) 2012-06-07
AU2011336692A1 (en) 2013-05-30
BR112013012799A8 (pt) 2018-01-09
CN103930105A (zh) 2014-07-16
ZA201304840B (en) 2014-04-30
WO2012075107A2 (en) 2012-06-07
EP2646015A4 (en) 2015-04-08
AU2011336692B2 (en) 2017-02-16
JP2014514243A (ja) 2014-06-19
PL2646015T3 (pl) 2020-11-30
EP2646015B1 (en) 2020-04-22
CA2817417C (en) 2020-12-29
RU2013119439A (ru) 2015-01-10

Similar Documents

Publication Publication Date Title
USD659247S1 (en) Dental implant
GEP20135919B (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
EP2590655A4 (en) COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
EP3715345A3 (en) Preparation of lfa-1 inhibitor and polymorph thereof
WO2012006474A3 (en) Compounds and methods for inhibiting phosphate transport
WO2012054110A3 (en) Compounds and methods for inhibiting phosphate transport
MY155662A (en) Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
GEP20146100B (en) Novel phenylimidazole derivative as pde10a enzyme inhibitor
WO2007139933A3 (en) Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
ZA201004694B (en) Use of a fertilizer containing l-amino acid for improving root growth and growth of mycorrhiza
RS53521B1 (en) PREPARATION AND THERAPY APPLICATIONS (2S, 3R) -N-2 - ((3-pyridinyl) methyl) -1-AZABICYCLO [2.2.2] OCT-3-IL) -3,5-DIFLUOROBENZAMIDE
TN2012000279A1 (en) Processes for the manufacture of a pharmaceutically active agent
MX2012007590A (es) Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral.
WO2012146980A3 (en) Preparation of fingolimod and its salts
USD673458S1 (en) Package face
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
MX2013005522A (es) Enantiomero activo de dodecil-2-(n,n-dimetilamino)-propionato.
WO2012023024A3 (en) Controlled release formulations of dronedarone
IL209583A0 (en) 1 - (2-ethyl-butyl) - cyclohexanecarboxylic acid ester as an intermediate in the preparation of pharmaceutically active amides
USD666431S1 (en) Plant support
USD666422S1 (en) Plant support
RS53896B1 (en) PANTENYL DOCOSAHEXAENOATE AND ITS USE FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
USD644956S1 (en) Flag canton
EP2548866A4 (en) NOVEL N-[3- (4-NITROPHENYLAMINO) -INDOL-2-IL-METHYLENE] N-[3- (4-NITROPHENYLAMINO) -INDOL-2-IL-METHYLENE] N-HYDROCHLORIDE ACTIVE COMPOUND WITH ANTI-INFLAMMATORY ACTION